Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation

  title={Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation},
  author={Asher Ornoy},
  journal={Pharmaceutical Research},
  • A. Ornoy
  • Published 6 February 2018
  • Psychology, Medicine, Biology
  • Pharmaceutical Research
IntroductionAttention deficit/hyperactivity disorder (ADHD) is a neurobehavioral problem found in 2–5% of adults. Stimulants and drugs that affect the dopaminergic, noradrenergic and/or serotonergic systems are effective treatment and are increasingly prescribed to women at child bearing age. It is consequently important that reliable information on the safety of these drugs in pregnancy is available so that appropriate therapeutic choices can be made.ResultsThe data on stimulants… 

The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review

The treating physician should judge the need for treatment during pregnancy in relation to the severity of the clinical symptoms, and methylphenidate is preferred over amphetamines because breast feeding is possible and bupropion seems to be the preferred drug.

Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review

There is substantial body of evidence to suggest that MPH is an effective and safe treatment option for adults with ADHD.

Stimulants: Caffeine, Cocaine, Amphetamine, and Other Stimulants

This chapter reviews the mechanisms of action of various stimulants, diagnostic features of different stimulant intoxication/withdrawal/use disorders, and evidence-based treatment modalities for these diagnostic entities.

Attention-Deficit/Hyperactivity Disorder and Women

Attention-deficit/hyperactivity disorder (ADHD) is most often diagnosed in boys and may be underdiagnosed in girls. This diagnostic gap can be partly explained by the fact that female symptoms are

Prevalence and determinants of attention deficit/hyperactivity disorder (ADHD) medication use during pregnancy: Results from the Quebec Pregnancy/Children Cohort

The aim of this study is to describe the prevalence of ADHD medication use among pregnant women—dosages and switches—and identify determinants of ADHD medications use.

The Course of ADHD during Pregnancy

This preliminary study provides novel insight into the course of ADHD during pregnancy, underscoring mood and family functioning as critical domains that may contribute to growing use of psychostimulants during pregnancy.



ADHD Treatment and Pregnancy

Discussions about ADHD treatment with women of childbearing age should be balanced, open and honest, acknowledging the lack of information on the possible risks to the offspring of continuing treatment, while also drawing attention to the possibleisks to both mother and child of discontinuing treatment.

The Novelty of Bupropion As a Dopaminergic Antidepressant for the Treatment of Adult Attention Deficit Hyperactive Disorder.

The present review highlights the novel effects of Bupropion in ADHD treatment, together with the help of other successful bio-psycho-social measures, which may be of immense benefit to the psychiatrists for treating their patients.

Use of Antidepressants During Pregnancy and Risk of Attention-Deficit/Hyperactivity Disorder in the Offspring

  • R. Figueroa
  • Psychology, Medicine
    Journal of developmental and behavioral pediatrics : JDBP
  • 2010
Children of mothers treated with bupropion during pregnancy have an increased risk of being diagnosed with ADHD; a possible causal effect needs to be further studied.

Increasing use of ADHD medications in pregnancy

There was a marked increase in the prevalence of use of any ADHD medication over the period of the study, from 0.2% for women with LMP dates in 1997–98 to 1.3% in 2013, according to the 2-sided Cochran-Armitage test for trend.

The Use of Central Nervous System Active Drugs During Pregnancy

An association between malformations and maternal use of anticonvulsants and notably valproic acid is well known from the literature and also demonstrated in the present study, and some other associations between drug exposure and outcome were found.

Atomoxetine, a Novel Treatment for Attention‐Deficit—Hyperactivity Disorder

Overall, atomoxetine therapy in patients with ADHD appears to be effective in controlling symptoms and maintaining remission, with the advantages being comparable efficacy with that of methylphenidate, a favorable safety profile, and non–controlled substance status.

Methylphenidate in Pregnancy: A Multicenter, Prospective, Comparative, Observational Study.

The present study suggests that methylphenidate does not seem to increase the risk for major malformations, and further studies are required to establish its pregnancy safety and its possible association with miscarriages.

Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review

While available evidence addressed mainly the efficacy and tolerability of psychostimulants and non-psychostimULants for ADHD core symptoms in the short term, further empirical support is needed for the non-pharmacological and multimodal treatments.

Selective Serotonin Reuptake Inhibitors during Pregnancy: Do We Have Now More Definite Answers Related to Prenatal Exposure?

Judging from the new population registry‐based studies with comparison to disease controls, there seems to be no demonstrable increase in the rate of major anomalies, prematurity, small for gestational age, or miscarriage, and the risk associated with treatment discontinuation appears to outweigh the fetal and neonatal risks of maternal treatment.